The biomarker landscape in mycosis fungoides and sézary syndrome

Abstract

The practice of preemptive individualized medicine is predicated on the discovery, development, and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis, and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome, highlighting the most promising molecules in different compartments. Further, we emphasize the need for continued multicenter efforts to validate available and new biomarkers and to develop prospective combinatorial panels of already discovered molecules.

This article is protected by copyright. All rights reserved.

http://ift.tt/2gyvHke